Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
134 hedge funds and large institutions have $847M invested in Verve Therapeutics in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 24 reducing their positions, and 14 closing their positions.
142% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 24
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
40% more call options, than puts
Call options by funds: $7M | Put options by funds: $4.99M
11% more funds holding
Funds holding: 121 → 134 (+13)
0.31% more ownership
Funds ownership: 99.94% → 100.25% (+0.31%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
27% less capital invested
Capital invested by funds: $1.16B → $847M (-$313M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.9M |
| 2 |
JP Morgan Chase
New York
|
+$10.7M |
| 3 |
CC
Casdin Capital
New York
|
+$9.57M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.55M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$9.55M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.38M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.39M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$4.06M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.49M |
VERV Hedge Fund Activity: Q3 2023 in Review
134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2023, worth a combined $847M — down 27% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VERV positions and 14 closed out — a net gain of 13 holders — while 58 added to existing stakes and 24 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Avidity Partners Management, cutting an estimated $9.55M.
- 134 institutional investors held Verve Therapeutics (VERV) as of Q3 2023, up from 121 in Q2 2023.
- Funds reported $847M of Verve Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
- 27 funds opened new Verve Therapeutics positions in Q3 2023 and 14 closed out, a net change of +13 holders.
- The largest Verve Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $11.9M added.
- The largest Verve Therapeutics seller in Q3 2023 was Avidity Partners Management, an estimated $9.55M sold.
Based on aggregated 13F filings for Q3 2023.